Casirivimab Plus Imdevimab Is Safe, Elicits Low Drug-Induced Immunogenicity Rate In Pediatric Outpatients With COVID-19, Research Finds

Infectious Disease Advisor (11/19, Nye) reports research found that “in combination, casirivimab plus imdevimab is safe and elicited a low drug-induced immunogenicity rate in pediatric outpatients with COVID-19.” The investigators said, “The findings support development of next-generation anti-SARS-CoV-2 [monoclonal antibodies] for at-risk pediatric patients.” The findings were published in The Journal of the Pediatric Infectious Diseases Society.